Amarin (AMRN) Beats Earnings & Misses Revenues In Q3
Zacks Investment Research | Nov 01, 2018 07:51AM ET
Amarin Corporation PLC (NASDAQ:AMRN) is a pharmaceutical company focused on developing innovating treatments for improving cardiovascular health. The company’s sole marketed drug, Vascepa, is approved as an adjunct to diet to reduce triglyceride levels in severe hypertriglyceridemia patients.
Amarin’s earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 16.25%, missing estimates in two quarters, beating the same once and meeting once.
Currently, Amarin’s has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Amarin reported an adjusted loss of 6 cents (excluding stock based compensation) per American depositary share which was narrower than the Zacks Consensus Estimate of loss of 9 cents.
Revenues Miss: Amarin posted revenues of $55.3 million, missing the consensus estimate of $61.5 million. However, it was up 24.7% year over year.
Key Stats: Adjusted selling, general and administrative expenses were up 46.8% at $44.4 million while adjusted research & development expenses increased 28.1% to $$13 million. Normalized prescriptions for Vascepa increased approximately 20% year-over-year. Effective Nov 2, Amarin will have no debt obligation with a fixed maturity date.
Share Price Impact: Shares were up a mere 0.1% in pre-market trading.
Amarin Corporation PLC Price and EPS Surprise
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.